CR20180465A - Composiciones y métodos para tratar artritis reumatoide - Google Patents

Composiciones y métodos para tratar artritis reumatoide

Info

Publication number
CR20180465A
CR20180465A CR20180465A CR20180465A CR20180465A CR 20180465 A CR20180465 A CR 20180465A CR 20180465 A CR20180465 A CR 20180465A CR 20180465 A CR20180465 A CR 20180465A CR 20180465 A CR20180465 A CR 20180465A
Authority
CR
Costa Rica
Prior art keywords
treat
compositions
methods
reumatoid arthritis
arthritis
Prior art date
Application number
CR20180465A
Other languages
English (en)
Inventor
Alexander; Boddy
Neil; Graham
Adelsberg Janet; Van
Hoogstraten Hubert; Van
Yong; Lin
Deborah; Bauer
Janie; Parrino
Rahul; Patel
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16305253.3A external-priority patent/EP3216461A1/en
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of CR20180465A publication Critical patent/CR20180465A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

La presente invención se refiere al uso de un anticuerpo anti-receptor de IL6 en monoterapia para tratar la artritis reumatoide y para mejorar la función física y la calidad de vida de un sujeto que padece artritis reumatoide.
CR20180465A 2016-03-07 2017-03-07 Composiciones y métodos para tratar artritis reumatoide CR20180465A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16305253.3A EP3216461A1 (en) 2016-03-07 2016-03-07 Compositions and methods for treating rheumatoid arthritis
EP16170664 2016-05-20
EP16306111 2016-09-05
PCT/US2017/021149 WO2017155990A1 (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis

Publications (1)

Publication Number Publication Date
CR20180465A true CR20180465A (es) 2019-03-04

Family

ID=58387910

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180465A CR20180465A (es) 2016-03-07 2017-03-07 Composiciones y métodos para tratar artritis reumatoide

Country Status (18)

Country Link
US (1) US20190100585A1 (es)
EP (1) EP3426295A1 (es)
JP (2) JP7166925B2 (es)
KR (2) KR20230093522A (es)
CN (1) CN109069642A (es)
AU (1) AU2017229364A1 (es)
BR (1) BR112018067851A2 (es)
CA (1) CA3016880A1 (es)
CL (1) CL2018002559A1 (es)
CR (1) CR20180465A (es)
EA (1) EA201892005A1 (es)
IL (2) IL261515B2 (es)
MX (1) MX2018010815A (es)
PH (1) PH12018501894A1 (es)
SG (2) SG11201807614SA (es)
TN (1) TN2018000312A1 (es)
TW (2) TWI747885B (es)
WO (1) WO2017155990A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN111110842B (zh) * 2017-11-30 2020-12-11 百奥泰生物制药股份有限公司 一种治疗il-6相关疾病的人源化抗体的液体制剂
CN112955222A (zh) * 2018-08-29 2021-06-11 里珍纳龙药品有限公司 用于治疗患有类风湿性关节炎的个体的方法和组合物
CN114206442A (zh) 2019-01-31 2022-03-18 赛诺菲生物技术公司 用于治疗幼年特发性关节炎的抗il-6受体抗体
MX2021012969A (es) 2019-04-24 2022-06-09 Sanofi Biotechnology Metodos de diagnostico y tratamiento de la artritis reumatoide.
WO2023020563A1 (en) * 2021-08-18 2023-02-23 Bio-Thera Solutions, Ltd. Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2868614A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
JP6657089B2 (ja) * 2013-11-22 2020-03-04 サノフィ・バイオテクノロジー 関節リウマチを治療するための組成物およびこれを使用する方法

Also Published As

Publication number Publication date
TN2018000312A1 (en) 2020-01-16
IL261515A (en) 2018-10-31
AU2017229364A1 (en) 2018-10-25
SG11201807614SA (en) 2018-10-30
IL308539A (en) 2024-01-01
JP2019507775A (ja) 2019-03-22
WO2017155990A1 (en) 2017-09-14
TWI747885B (zh) 2021-12-01
PH12018501894A1 (en) 2019-05-15
EP3426295A1 (en) 2019-01-16
TWI819435B (zh) 2023-10-21
NZ746988A (en) 2023-10-27
BR112018067851A2 (pt) 2019-02-05
TW201808993A (zh) 2018-03-16
CA3016880A1 (en) 2017-09-14
IL261515B2 (en) 2024-04-01
CL2018002559A1 (es) 2019-03-01
SG10202012182YA (en) 2021-01-28
KR20230093522A (ko) 2023-06-27
TW202239767A (zh) 2022-10-16
EA201892005A1 (ru) 2019-02-28
MX2018010815A (es) 2019-01-10
JP2023011711A (ja) 2023-01-24
US20190100585A1 (en) 2019-04-04
CN109069642A (zh) 2018-12-21
IL261515B1 (en) 2023-12-01
JP7166925B2 (ja) 2022-11-08
KR20180114955A (ko) 2018-10-19

Similar Documents

Publication Publication Date Title
CR20180465A (es) Composiciones y métodos para tratar artritis reumatoide
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
MX2022009463A (es) Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso.
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
BR112014019331A8 (pt) anticorpos para cd47 e métodos de uso desses
CR20160314A (es) Anticuerpos anti-cd3 y metodos de uso
CR20180225A (es) Anticuerpo anti-tigit y métodos de uso
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
CO2020013392A2 (es) Receptores quiméricos de dll3 y métodos para su uso
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
AR081750A1 (es) Anticuerpos anti-cd40
MX2020011993A (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
BR112017013111A2 (pt) métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo
ECSP17031725A (es) Receptores quiméricos de anitígeno anti-clon y métodos de uso
CR20160379A (es) Anticuerpos biespecificos anti-il 13/il-17 y sus usos
CL2018000298A1 (es) Anticuerpos anti-cd154 y métodos de uso de estos.
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
BR112018008900A8 (pt) composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
CO2019013718A2 (es) Anticuerpos anti-trkb